Skip to main content
KoBioLabs, Inc. logo

KoBioLabs, Inc. — Investor Relations & Filings

Ticker · 348150 ISIN · KR7348150004 KO Manufacturing
Open in API
Filings indexed 174 across all filing types
Latest filing 2021-02-16 Earnings Release
Country KR South Korea
Listing KO 348150

About KoBioLabs, Inc.

http://kobiolabs.com/en/

KoBioLabs, Inc. is a biotechnology company that develops innovative microbiome-based therapeutics. The company utilizes its proprietary Smartiome® platform, an integrated system for discovering novel drug candidates that employs AI-driven multi-omics analysis and a comprehensive microbiome library with a reverse-translation approach. KoBioLabs is focused on creating a pipeline of new drugs to treat a range of immune, metabolic, and brain disorders. The company also applies advanced technologies, including a microbe-based drug delivery system (mDDS) and biofoundry techniques, to enhance the efficacy of its treatments and address unmet medical needs.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (GohBioLab) regarding a significant change in revenue or profit/loss structure (30% or more). This is a standard disclosure requirement for companies listed on the KRX (Korea Exchange) when financial results deviate significantly from the previous period. Since it provides key financial highlights (revenue, operating profit, net income) and explains the reasons for the change, it functions as an initial announcement of financial results, which falls under the Earnings Release category. FY 2020
2021-02-16 Korean
파생상품거래손실발생
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure from a Korean company (Gohibiolab) regarding a 'Loss from Derivatives Transaction'. It details the nature of the loss (valuation loss on convertible preferred shares), the amount, and the impact on equity. Since this is a specific regulatory disclosure of a material event (financial loss) filed with the exchange, it falls under the general regulatory filing category.
2021-02-16 Korean
기타경영사항(특허권취득)(자율공시)(짧은 사슬 지방산 생성 장내 세균 군집의 변화를 이용한 알코올성 간 질환의 진단 및 치료용 조성물)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent by the company '고바이오랩'. It details the patent name, content, and utilization plan. Since it is a regulatory announcement regarding a specific corporate event (patent acquisition) that does not fit into financial reporting or governance categories, it falls under the general regulatory filing category.
2021-02-01 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and logistics of an Investor Relations (IR) event (기업설명회). It provides the date, location, purpose, and method of the event, and mentions that IR materials will be posted on the company website and the Korea Exchange (KIND) system. Since this is an announcement of an upcoming event and the availability of materials rather than the presentation itself, it falls under the category of a Report Publication Announcement or general regulatory filing announcement.
2021-01-19 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the suspension of share registration (shareholder register closure) for the purpose of determining shareholders for an upcoming Annual General Meeting. It does not contain full financial statements or meeting materials, but rather serves as a formal regulatory announcement of a corporate action. Given it does not fit into specific categories like dividend announcements or share buybacks, it falls under the general regulatory filing category.
2020-12-18 Korean
기타경영사항(자율공시)(상환전환우선주의 보통주 전환청구)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from a Korean company (고바이오랩) regarding the conversion of Redeemable Convertible Preference Shares (RCPS) into common stock. This involves a change in the company's capital structure and share count. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'Share Issue/Capital Change' (SHA) category.
2020-12-14 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.